Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on May 19, 2021. The report addresses a specific corporate event under Item 8.01 (Other Events) involving a collaboration with GeneTx Biotherapeutics LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes and Events
- Clinical Study Clearance: On May 19, 2021, Ultragenyx and GeneTx Biotherapeutics LLC announced they received clearance from Health Canada.
- Scope: The clearance permits the commencement of a clinical study for the investigational therapy GTX-102.
- Indication: The study targets the treatment of Angelman syndrome in Canada.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the announcement of the regulatory clearance. The document references a press release (Exhibit 99.1) for further details on the event.
Key Facts for Investor Verification
- Verify the specific design and enrollment criteria of the GTX-102 clinical study in Canada via the referenced press release.
- Confirm the current development status of GTX-102 in other jurisdictions (e.g., FDA status in the US).
- Review the terms of the collaboration agreement between Ultragenyx and GeneTx Biotherapeutics LLC regarding GTX-102.